Celyad: Some Questions For Management – Seeking Alpha
|
Celyad: Some Questions For Management
Seeking Alpha Celyad is developing CAR–T therapies for solid tumors. CAR–T was historically developed only targeting hematologic cancers, one reason for which was that the receptor, CD19, was specific to the B-cell surface. This restricted CAR–T usage to the … |
